Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Exclusive: Walgreens has explored taking drug store chain private - sources

Published 05/11/2019, 19:14
Updated 05/11/2019, 19:17
Exclusive: Walgreens has explored taking drug store chain private - sources

By Greg Roumeliotis and Mike Spector

(Reuters) - Walgreens Boots Alliance Inc (O:WBA) has been exploring whether to go private following private equity interest in the U.S drug store chain, according to people familiar with the matter.

In recent months, Walgreens has held preliminary discussions with some of the world's largest private equity firms about putting together what would be the biggest ever leveraged buyout, the sources said. Walgreens has a market value of $55 billion (£42.74 billion), and its debt at the end of August totaled $17 billion.

Walgreens has tasked investment bank Evercore Partners Inc (N:EVR) with exploring whether a deal can be put together, the sources said, cautioning that a deal is far from certain.

Many private equity firms have pushed back on the idea, concerned about Walgreens' business prospects and the challenges of financing the deal, the sources added.

A leveraged buyout of Walgreens would likely require the participation of several private equity firms, each writing large checks, at a time when many of them have lost their appetite for teaming together on so-called club deals. Many of those takeovers were completed during a boom preceding the 2008 financial crisis and subsequently struggled or collapsed.

Walgreens Chief Executive Stefano Pessina, who is the company's largest shareholder with a 16% stake, could roll his equity into the deal to help finance the transaction, one of the sources said.

Walgreens has also contemplated divesting some of its assets, such as its 27% stake in drug wholesaler AmerisourceBergen Corp (N:ABC), to provide more funding, one of the sources added.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The sources asked not to be identified because the matter is confidential. Walgreens declined to comment, while Evercore did not immediately respond to a request for comment.

Walgreens shares rose 8% to $64.12 in New York on the news on Tuesday. The stock had lost 28% of its value in the last 12 months, compared to a 13% rise in the S&P 500 Index (INX).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.